News

Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results
UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus ...
pharmaphorum1d
Data at EULAR back Biogen, UCB's first-in-class lupus drug
Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...
Nasdaq2d
UCB & Biogen : Phase 3 Trial Of Dapirolizumab Pegol In Systemic Lupus Erythematosus Meets Main Goal
(RTTNews) - UCB (UCB) and Biogen Inc. (BIIB) presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate.
Nasdaq2d
UCB and Biogen Announce Positive Efficacy Results for Dapirolizumab Pegol in Phase 3 PHOENYCS GO Study for Systemic Lupus Erythematosus
UCB is listed on Euronext Brussels (symbol: UCB). Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s ...
MedPage Today on MSN2d
First-in-Class Lupus Drug Aces Phase III Test
BARCELONA -- A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory ...
Finanznachrichten2d
Biogen Inc.: Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
10 Dapirolizumab pegol is presently in Phase 3 clinical development for the treatment of systemic lupus erythematosus (SLE) under a collaboration between UCB and Biogen. 11 About UCB UCB ...
Biogen (BIIB) Receives a Hold from Wedbush
In a report released today, Laura Chico from Wedbush maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $121.00. The company’s shares closed y ...
Piper Sandler Keeps Their Hold Rating on Biogen (BIIB)
In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target of $115.00. The company’s shares ...